Research Use Only.
KIRhub outputs are computational research artifacts. They are not validated for clinical decision-making, diagnosis, or treatment.
KIRhub 2.0
· v2
Dashboard
Workspace
Knowledge Graph
Ependymoma Hub
V1
V2
Sign in
Ask KIRhub
Your entry point to explore every drug, kinase, variant, sample, cohort and insight.
researcher
clinician
⚡
Guided
💬
Ask freely — just type below
Best drug (verdict)
Pathway-reversal verdict for one sample: drugs ranked by predicted reversal.
Drug summary
Metadata, FDA status and selectivity for one kinase-inhibitor drug.
Off-target / selectivity
What a drug hits beyond its intended target, and how selective it is.
Resistance landscape
Target inhibition profile used to reason about a drug's resistance landscape.
Alternatives for a case
Ranked alternative drugs for a sample from its pathway-reversal verdict.
Tumor twins
Nearest-neighbour tumor samples in the atlas embedding.
Clinical trials
Search ClinicalTrials.gov by drug, target, or condition.
Cohort consensus drug
Consensus pathway-reversal verdict across a whole cohort.
Drug-desert status
Atlas tumor states with poor drug coverage (unmet need).
Pathway twins
Samples most similar to a given sample by atlas pathway embedding.
Try asking:
How selective is imatinib?
What drugs inhibit CDK6?
Repurposing candidates for dasatinib
Which cohorts have the most samples?
Send
💬
Ask KIRhub